Immunomedics, UCB Rework Agreement for Lupus Drug
Immunomedics Inc. and development partner UCB SA revised their development, collaboration and license agreement for the exclusive worldwide rights to develop, market and sell Immunomedics' epratuzumab for autoimmune disease indications.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter